More than 50 million Hispanics call the United States home and in 2013, Hispanic Americans accounted for nearly one-third of the non-elderly uninsured population. As Hispanic Heritage Month begins, we’re showcasing our new Spanish-language resources to help demystify health coverage and equip patients to make the best decisions for them and their families.
Buying health insurance is confusing, whether you’re shopping for the first time or looking at your coverage every year. Our new Spanish-language resources seek to make it a little easier. AccessBetterCoverage.org/espanol offers resources on health care terms, health insurance and tips for shopping for health coverage.The new page has helpful resources for understanding how health insurance works and what to expect from your coverage. The site includes:
- A series of Spanish-language white board videos addressing topics like health insurance 101, how medicines are covered and how insurers limit the use of medicines.
- A glossary of health insurance terms like deductible and copay.
- Lists of questions to ask and consider when looking for coverage.
Check out all of our Spanish-language resources here: http://accessbettercoverage.org/espanol.
Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.